Neuroblastoma, an embryonal tumour of the peripheral sympathetic nervous system, accounts for approximately 15% of all deaths due to childhood cancer 1 . High-risk neuroblastomas are rapidly progressive; even with intensive myeloablative chemotherapy, relapse is common and almost uniformly fatal 2, 3 . Here we report the detection of previously unknown mutations in the ALK gene, which encodes a receptor tyrosine kinase, in 8% of primary neuroblastomas. Five non-synonymous sequence variations were identified in the kinase domain of ALK, of which three were somatic and two were germ line. The most frequent mutation, F1174L, was also identified in three different neuroblastoma cell lines. ALK complementary DNAs encoding the F1174L and R1275Q variants, but not the wild-type ALK cDNA, transformed interleukin-3-dependent murine haematopoietic Ba/F3 cells to cytokine-independent growth. Ba/F3 cells expressing these mutations were sensitive to the small-molecule inhibitor of ALK, TAE684 (ref. 4 ). Furthermore, two human neuroblastoma cell lines harbouring the F1174L mutation were also sensitive to the inhibitor. Cytotoxicity was associated with increased amounts of apoptosis as measured by TdT-mediated dUTP nick end labelling (TUNEL). Short hairpin RNA (shRNA)-mediated knockdown of ALK expression in neuroblastoma cell lines with the F1174L mutation also resulted in apoptosis and impaired cell proliferation. Thus, activating alleles of the ALK receptor tyrosine kinase are present in primary neuroblastoma tumours and in established neuroblastoma cell lines, and confer sensitivity to ALK inhibition with small molecules, providing a molecular rationale for targeted therapy of this disease.
In a genome-wide analysis of primary neuroblastomas using single-nucleotide polymorphism (SNP) arrays, we noted high-level amplification of the ALK (anaplastic lymphoma kinase) gene 5 . To determine the frequency of this amplification, we analysed 94 tumours with amplification of the oncogene MYCN by fluorescence in situ hybridization (FISH), and documented 14 (15%) with concomitant ALK amplification ( Supplementary Fig. 1 ), which was not detected in 51 tumours without MYCN amplification (P 5 0.0016). None of the tumours had ALK rearrangements, such as those that have been found in other tumour types with ALK translocations [6] [7] [8] [9] .
We reasoned that in tumours without ALK amplification or translocation, acquired somatic mutations or germline sequence variants might contribute to oncogenicity. DNA re-sequencing of the ALK open reading frame in primary neuroblastomas identified five new non-synonymous sequence variations in conserved positions in the tyrosine kinase domain in 7 out of 93 samples (8%; Table 1 and Supplementary Fig.2 ). None of these variants were previously identified SNPs or known somatic mutations, on the basis of analysis of dbSNP and Sanger databases or by the genotyping of 270 samples derived from the International Hap Map Consortium 10 .
Sequence analysis of matched normal samples from these patients showed that two of the sequence variants were germ line and three represented somatically acquired mutations (Table 1) . The most common mutation, identified in 4.3% (4 out of 93) of the primary tumours, was a recurrent cytosine-to-adenine change in exon 23 that results in a phenylalanine-to-leucine substitution at codon 1174 (F1174L) within the kinase domain. Most of the patients with somatic ALK mutations had metastatic disease characterized by MYCN amplification, although one patient with the F1174L mutation had localized disease with favourable histology and unamplified MYCN (Supplementary Table 1 ). Four of the five ALK mutations involve residues that correspond to those affected by known activating mutations in the EGFR gene [11] [12] [13] [14] ( Supplementary Figs 2  and 3 ). The F1174 residue corresponds to V769 in EGFR, which is in a region of frequent mutation in both the EGFR 11 and ERBB2 (ref. 12) genes. The F1245C mutation corresponds to L833V in EGFR, a gefitinib-resistant mutation in lung cancer (H.G. and M.M., unpublished observations). The R1275Q mutation is located adjacent to the homologous position of L858R in EGFR, which is the most common EGFR mutation in lung cancer 13, 14 .
The functional consequences of four of the mutations, T1151M, F1174L, A1234T and R1275Q, were determined by testing their abilities to transform interleukin-3 (IL-3)-dependent murine lymphoid Ba/F3 cells to cytokine-independent growth. Reductions in IL-3 concentration by 100-fold to 0.01 ng ml 21 resulted in a clear difference in cell proliferation, with the Ba/F3 cells expressing F1174L and R1275Q mutations having much higher cell numbers relative to those transduced with wild-type ALK or the T1151M mutation (Fig 1a) . To generate IL-3-independent lines, we reduced the IL-3 concentration by half in successive passages of each transduced Ba/F3 line. After five passages, the Ba/F3 cells expressing the F1174L and the R1275Q ALK mutations, as well as NPM-ALK, were able to grow in medium completely lacking IL-3, whereas cells expressing T1151M or wild-type ALK did not survive. Moreover, when expressed in Ba/F3 cells, the F1174L allele, and to a lesser extent, the R1275Q allele, were associated with constitutive phosphorylation of ALK ( Fig. 1b ). In contrast, neither the T1151M nor the A1234T alleles showed ALK phosphorylation. Expression of the F1174L ALK protein in IL-3deprived Ba/F3 cells was also associated with phosphorylation of downstream targets of ALK signalling such as STAT3 and AKT, whereas R1275Q was associated with phosphorylation of ERK1/2 and AKT ( Fig. 1b) . Together, these studies demonstrate that the ALK mutant proteins F1174L and R1275Q possess gain-of-function kinase activity that can sustain important signalling pathways in Ba/ F3 cells cultured in the absence of IL-3.
The Ba/F3 assay has been validated for a broad spectrum of oncogenic tyrosine kinase alleles including mutant EGFR 15 and FLT3 (ref. 16) , and thus we treated Ba/F3 cells expressing each of the ALK mutations with increasing concentrations of TAE684, a highly potent ALK inhibitor 4, 17, 18 . The activating mutation, F1174L, was found to be extremely sensitive to TAE684, with a half-maximal inhibitory concentration (IC 50 ) of 8 nM, identical to that of NPM-ALK-expressing Ba/F3 cells. The R1275Q mutation was also sensitive to TAE684, albeit with a much higher IC 50 of 328 nM. In contrast, Ba/F3 cells expressing internal tandem duplications of the FLT3 gene (FLT3-ITD) or wild-type ALK, did not respond to TAE684 (IC 50 4.6 mM; Fig. 1c ).
Analysis of the ALK gene in a panel of 30 neuroblastoma cell lines revealed sequence variants in 6, including 3 different cell lines containing the F1174L mutation (KELLY, SH-SY5Y and LAN-1), which was also the most common mutation in the primary tumours (Table 1 ). An R1275Q mutation, identical to the one found in primary sample 411, was also detected in the SMS-KCNR cell line. We observed dose-dependent growth inhibition of the SH-SY5Y (F1174L) and KELLY (F1174L) neuroblastoma cell lines with increasing concentrations of TAE684 (IC 50 values of 258 and 416 nM, respectively; Fig. 2a ). These results are in agreement with data from a recent study showing sensitivity of these cell lines to TAE684 (ref. 19) . Of note, the SMS-KCNR cell line expressing the ALK R1275Q mutation was resistant to TAE684 (IC 50 of 4.9 mM; Fig. 2a ), although Ba/F3 cells expressing this mutation became IL-3-independent and were sensitive to the inhibitor (Fig. 1c ). Neuroblastoma cell lines without ALK mutations, including IMR5, were also resistant to TAE684 ( Fig. 2a and Supplementary Fig. 4a ). Treatment with TAE684 (200 nM) resulted in increased apoptosis in KELLY (F1174L) and SH-SY5Y (F1174L) cells, but not in the SMS-KCNR (R1275Q) and IMR5 (wild type) cells (Fig. 2b) . Cytotoxicity was also associated with G1-phase arrest and substantial reductions in S-phase cell fractions ( Supplementary Fig. 4b ).
After treatment with TAE684 (100 nM), the sensitive cell lines SH-SY5Y (F1174L) and KELLY (F1174L) demonstrated reduced phosphorylation of ALK, ERK1/2 and AKT, and STAT3 to a lesser extent ( Supplementary Fig 4c) . In contrast, there was no apparent effect on the phosphorylation of AKT and STAT3 in the resistant cell line IMR5 (wild type), although there was a slight reduction in the phosphorylation of ERK1/2. Moreover, knockdown of ALK in the KELLY and SH-SY5Y cell lines (F1174L), but not the inhibitor-resistant SMS-KCNR line (R1275Q), was associated with a reduction in cell proliferation and increased apoptosis ( Fig. 2c, d) . In neuroblastoma, ALK is detected as both a 220 kDa protein, reflecting the glycosylated protein encoded by the transduced ALK cDNA and a second protein of ,140 kDa ( Fig. 2c, inset) , which has been documented by several investigators and probably represents an as yet uncharacterized splice variant-encoded isoform of ALK [20] [21] [22] . The resistance of the SMS-KCNR cell line is apparently not due to any difference between the R1275Q and F1174L mutations in ALK activation per se, because both of these mutations transform Ba/F3 cells to IL-3 independence and the transformed cells respond to the inhibitor (Fig. 1c) . Instead, we suspect that other molecular aberrations, such as co-activation of other receptor tyrosine kinases 23, 24 , could have been acquired during culture that render this cell line independent of activated ALK for growth and viability.
We observed that ALK was expressed at substantially lower levels in the TAE684-sensitive neuroblastoma cell lines (KELLY (F1174L) and SH-SY5Y (F1174L)) than in the remaining cell lines harbouring either wild-type ALK or the R1275Q mutation ( Fig. 3a) . However, TAE684 inhibition of ALK kinase activity resulted in an increase in the ALK protein level in the sensitive KELLY (F1174L) cell line, but not in the IMR5 (wild type; Fig. 3b ) cell line. Blockade of protein degradation by the proteasome inhibitor MG-132 resulted in increased ALK levels in KELLY (F1174L) cells, but not in IMR5 cells (Fig. 3c ), consistent with a higher turnover rate in cells with the constitutively activated mutant ALK protein.
The studies reported here demonstrate previously unrecognized activating mutations affecting critical residues within the ALK kinase domain and indicate that ALK has potential as a therapeutic target in neuroblastoma. Our results with the ALK small-molecule inhibitor, TAE684, demonstrate that most of the neuroblastoma cell lines harbouring activating ALK mutations are dependent on the altered ALK protein for survival. One exception is the activating R1275Q allele, which when expressed by itself in Ba/F3 cells is sensitive to treatment with TAE684, but not in the SMS-KCNR neuroblastoma background. This observation, together with the lack of transforming activity of the T1151M and the A1234T alleles, supports the emerging concept that mutations affecting critical domains of cancer genes must be studied both genetically and functionally to validate their potential as therapeutic targets 16 . Thus, it will be important to test the ability of each mutant ALK protein identified in patient tumour samples to confer IL-3 resistance in Ba/F3 cells and mediate sensitivity to ALK inhibitory drugs as they move into therapeutic trials. One sensitive cell line, KELLY (F1174L), harboured both an activating ALK mutation and MYCN amplification, suggesting that a subset of very high risk MYCN-amplified neuroblastomas may respond to treatment with an ALK inhibitor. Although established neuroblastoma cell lines with high levels of wild-type ALK expression did not respond to ALK inhibitors in our study, it will be important to evaluate whether the larger group of neuroblastoma patients expressing wild-type ALK proteins have responses when ALK inhibitors are tested in vivo in the natural tumour microenvironment, which includes exposure to the effects of ALK ligands 25, 26 .
METHODS SUMMARY
DNA sequencing. Primers were designed to cover the 29 exons of ALK and characterized using 3 Coriell DNAs. Passing primers and samples were amplified by PCR and sequenced bidirectionally on an ABI 3730xl automated sequencer (Applied Biosystems). Automated analysis and coverage statistics were generated with SNP Compare (an in-house package using PolyPhred 27 and PolyDHAN (D. Richter et al., manuscript in preparation)). Bidirectional sequence traces were analysed with Mutation Surveyor (Softgenetics, version 3.10) and manual review. Genotyping was performed by primer extension mass spectrometry. Cell culture. Neuroblastoma cell lines were cultured in RPMI-1640 containing L-glutamine and 10% fetal bovine serum (FBS; Sigma-Aldrich). Ba/F3 cells were maintained in RPMI-1640 supplemented with 10% FBS and 0.5 ng ml 21 murine IL-3 (Millipore). DNA constructs and retrovirus production. ALK mutations were engineered using the QuikChange II Site-Directed Mutagenesis Kit (Stratagene). The LETTERS mutant cDNAs were subcloned into the pMSCV-Neo-luc retroviral vector. Cotransfection of 293T cells and infection of Ba/F3 cells with retroviral supernatants were performed as described previously 16 . Transduced Ba/F3 cells were selected with G418 for 7 days and subjected to Ficoll separation to isolate surviving cells. Cytokine independence assays. Ba/F3 cells transduced with each of the pMSCV-Neo-luc constructs were seeded at 1 3 10 5 ml 21 and treated with 1, 0.1 and 0.01 ng ml 21 IL-3 for 72 h. The number of viable cells was determined by trypan blue exclusion using a Vi-CELL Series Cell Viability Analyzer (Beckman Coulter). Drug sensitivity assay. Cell viability was tested 72 h after addition of the compound by CellTiter-Glo Luminescent Cell Viability Assay (Promega). IC 50 values were calculated by nonlinear regression (variable slope) using GraphPad Prism 5 software.
Immunoblotting. Immunoblotting was performed as described previously 16 . Antibodies are listed in Supplementary Methods. Proteasome inhibitor treatment. 1 3 10 6 cells were treated with the proteasome inhibitor MG-132 (Sigma-Aldrich) for 1 h, washed in PBS and immunoblotted as described previously 16 .
